Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,732 active trials43 approved drugs557 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,051 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05394259 | A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer | active not recruiting | Phase 1 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06225011 | Fluoxetine for the Modification of Colorectal Tumor Immune Cells Before Surgery in Patients With Colorectal Cancer | recruiting | Phase 1 | 10 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 20, 2026 |
| clinicaltrials |
| NCT07619313 | AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer | recruiting | Phase 1 | 46 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07777211 | A Phase I/IIa Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer | active not recruiting | Phase 1 / Phase 2 | 52 | Beijing Gene Key Life Technology Co., LtdINDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT03454035 | Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors | recruiting | Phase 1 | 45 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05220046 | Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers | completed | Phase 1 | 18 | University of NebraskaOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05497336 | A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer | terminated | Phase 1 | 8 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06084884 | A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma(ATHENA) | active not recruiting | Phase 1 / Phase 2 | 94 | AstraZenecaINDUSTRY | 3 | Aug 19, 2026 | clinicaltrials |
| NCT07175389 | JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure | not yet recruiting | Phase 1 / Phase 2 | 10 | West China HospitalOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07214298 | Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 35 | Roswell Park Cancer InstituteOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07636785 | A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors(SPKTAHC) | recruiting | Phase 1 / Phase 2 | 111 | VM Discovery, Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT03096054 | A Phase I Trial of LY3143921 Hydrate in Solid Tumours | completed | Phase 1 | 69 | Cancer Research UKOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT04432597 | HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers | completed | Phase 1 / Phase 2 | 39 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2026 | clinicaltrials |
| NCT05435014 | T-ACE Oil by TAE/TACE in Patients With Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 2 | T-ACE Medical Co., LtdINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06233331 | Use of ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV | not yet recruiting | Phase 1 | 9 | Emory UniversityOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06427798 | Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy | recruiting | Phase 1 / Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06764316 | A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer(BANTAM-01) | recruiting | Phase 1 | 148 | BayerINDUSTRY | 9 | Aug 18, 2026 | clinicaltrials |
| NCT07025889 | IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer | recruiting | Phase 1 / Phase 2 | 55 | Ruijin HospitalOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07182149 | A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors | recruiting | Phase 1 | 150 | Normunity AccelCo, Inc.INDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT04895709 | A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 1,109 | Bristol-Myers SquibbINDUSTRY | 8 | Aug 17, 2026 | clinicaltrials |
| NCT04942626 | Capecitabine-based Chemoradiotherapy in Combination With the IL-1 Receptor Antagonist Anakinra for Rectal Cancer Patients(ACO/ARO/AIO-21) | completed | Phase 1 | 12 | Goethe UniversityOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05791448 | AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease | suspended | Phase 1 | 36 | University of Southern CaliforniaOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05919264 | FOG-001 in Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 619 | Parabilis Medicines, Inc.INDUSTRY | 2 | Aug 17, 2026 | clinicaltrials |
| NCT07157033 | A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.(XER-001) | recruiting | Phase 1 / Phase 2 | 36 | Xerient PharmaINDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05038098 | Magnetic Sentinel Lymph Node Mapping in Gastric Cancer | not yet recruiting | Phase 1 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT05722327 | Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer | active not recruiting | Phase 1 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07700212 | A Phase 1 Trial Of Safety And Initial Efficacy Of Vagal Nerve Blockade For Cancer-Induced Cachexia In Patients With Metastatic Pancreatic Adenocarcinoma | not yet recruiting | Phase 1 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT02830724 | Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers | recruiting | Phase 1 / Phase 2 | 124 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT04522336 | Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer | completed | Phase 1 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05288205 | Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation | recruiting | Phase 1 / Phase 2 | 240 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05572684 | A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 97 | NextCure, Inc.INDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05701488 | SIRT With Tremelimumab and Durvalumab for Resectable HCC | active not recruiting | Phase 1 | 20 | Jiping Wang, MD, PhDOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05985655 | Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors(ELUCIDATE) | recruiting | Phase 1 / Phase 2 | 230 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.INDUSTRY | 3 | Aug 13, 2026 | clinicaltrials |
| NCT06399757 | A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 100 | Apollo Therapeutics LtdINDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06795022 | First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours(RHEA-1) | recruiting | Phase 1 / Phase 2 | 304 | AstraZenecaINDUSTRY | 7 | Aug 13, 2026 | clinicaltrials |
| NCT07053072 | PD-1 mRNA LNP Vaccine for Advanced Primary Hepatocellular Carcinoma. | recruiting | Phase 1 | 9 | West China HospitalOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07066657 | A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 572 | ArriVent BioPharma, Inc.INDUSTRY | 2 | Aug 13, 2026 | clinicaltrials |
| NCT07763301 | YMN-136 Vaccine for Patients With Advanced Hepatobiliary and Pancreatic Malignancies | recruiting | Phase 1 | 9 | West China HospitalOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT04354246 | COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies | completed | Phase 1 | 94 | Compugen LtdINDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04609592 | Study of PRRT in Metastatic, WHO Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery | active not recruiting | Phase 1 | 10 | Stanford UniversityOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05737615 | PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers With Elevated CA19.9 | withdrawn | Phase 1 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 0 | Aug 12, 2026 | clinicaltrials |
| NCT06840886 | A Study of PHST001 in Advanced Solid Tumors | recruiting | Phase 1 | 272 | Pheast TherapeuticsINDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07272642 | A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors.(DUNP19) | not yet recruiting | Phase 1 | 16 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07277322 | Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases | recruiting | Phase 1 / Phase 2 | 24 | Dan FengOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07761286 | Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 288 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04068610 | COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC | active not recruiting | Phase 1 / Phase 2 | 61 | MedImmune LLCINDUSTRY | 5 | Aug 11, 2026 | clinicaltrials |
| NCT05592626 | A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors(START-001) | recruiting | Phase 1 / Phase 2 | 366 | Marengo Therapeutics, Inc.INDUSTRY | 4 | Aug 11, 2026 | clinicaltrials |
| NCT05706129 | A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 270 | Lumara Bio Oncologics GmbHINDUSTRY | 2 | Aug 11, 2026 | clinicaltrials |
| NCT06242470 | A Study of MGC026 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 250 | MacroGenicsINDUSTRY | 3 | Aug 11, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 20, 2026source: clinicaltrials